Trial Search Results

Development of Vitamin D as a Therapy for Breast Cancer - Phase 2

This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: United States Department of Defense

Stanford Investigator(s):


  • Drug: Vitamin D


Phase 2



   - Undergoing core needle biopsy for a breast abnormality suspicious for breast cancer.

   - Has undergone a core needle biopsy demonstrating breast cancer and has not yet had any
   further therapy, provided the core needle biopsy is available for analysis.

   - No prior therapy for breast cancer within the past 5 years.

   - 18 years of age or older.

   - Ability to understand and the willingness to sign a written informed consent document.


   - History of parathyroid disease, hypercalcemia, or kidney stones.

   - Supplemental vitamin D other than from a standard multiple vitamin or from standard
   formulations of calcium and vitamin D (eg, calcium citrate with vitamin D) within the
   prior 6 months.

   - History of renal failure requiring dialysis or kidney transplantation.

   - Pregnant or nursing

   - Receiving supplemental calcium > 1200 mg calcium per day during study.

   - Initial treatment of breast cancer will not be with breast-conserving surgery or

   - Locally-advanced breast cancer

   - Plans for neoadjuvant chemotherapy, hormonal therapy, or other systemic therapy

   - Plans for preoperative radiation therapy

   - Plans for breast cancer surgery, and does not allow for at least 10 days of vitamin D

   - Any condition potentially interfering with subjects ability to comply with taking
   study medication.

   - Any medical condition that would potentially interfere with vitamin D absorption, such
   as celiac sprue, ulcerative colitis.

   - Current participation in another research study that would increase risk to subject,
   in the opinion of the investigators

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Charlene Kranz